In this article, I will feature one healthcare stock that has seen intensive insider selling during the last 30 days. Intensive insider selling can be defined by the following three criteria:
- The stock was sold by three or more insiders within one month.
- The stock was not purchased by any insiders in the month of intensive selling.
- At least two sellers decreased their holdings by more than 10%.
Thermo Fisher Scientific (TMO) provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics.
Insider selling during the last 30 days
Here is a table of Thermo Fisher's insider-trading activity during the last 30 days by insider.
Name | Title | Trade Date | Shares Sold | Rule 10b5-1 | Current Ownership | Decrease In Ownership |
Thomas Loewald | SVP | Feb 6 | 22,437 | No | 40,483 shares + 12,313 options | 29.8% |
Peter Wilver | CFO | Feb 6-7 | 91,897 | No | 104,305 shares | 46.8% |
Jim Manzi | Director | Feb 6 | 6,000 | No | 48,397 shares | 11.0% |
William Parrett | Director | Feb 6 | 18,000 | No | 11,188 shares | 61.7% |
There have been 138,334 shares sold by insiders during the last 30 days.
Insider selling by calendar month
Here is a table of Thermo Fisher's insider-trading activity by calendar month.
Month | Insider selling / shares | Insider buying / shares |
February 2014 | 138,334 | 0 |
January 2014 | 0 | 0 |
December 2013 | 0 | 0 |
November 2013 | 0 | 0 |
October 2013 | 0 | 0 |
September 2013 | 4,000 | 0 |
August 2013 | 4,000 | 0 |
July 2013 | 80,700 | 0 |
June 2013 | 261,807 | 0 |
May 2013 | 41,460 | 0 |
April 2013 | 0 | 0 |
March 2013 | 4,761 | 0 |
February 2013 | 5,756 | 0 |
January 2013 | 105,280 | 0 |
There have been 646,098 shares sold, and there have been zero shares purchased by insiders since January 2013.
Financials
Thermo Fisher reported the full-year 2013 financial results on January 30 with the following highlights:
Revenue | $13.1 billion |
Net income | $1.3 billion |
Cash | $5.8 billion |
Debt | $10.5 billion |
Outlook
Thermo Fisher's 2014 guidance is as follows:
Revenue | $16.63-$16.83 billion |
EPS | $6.70-$6.90 |
Competition
Thermo Fisher's competitors include Agilent Technologies (A), and Becton, Dickinson and Company (BDX). Here is a table comparing these companies.
Company | TMO | A | BDX |
---|---|---|---|
Market Cap: | 42.61B | 19.72B | 21.37B |
Employees: | 39,000 | 20,600 | 30,000 |
Qtrly Rev Growth (yoy): | 0.06 | -0.03 | 0.06 |
Revenue: | 13.09B | 6.78B | 8.13B |
Gross Margin: | 0.44 | 0.52 | 0.52 |
EBITDA: | 2.79B | 1.39B | 2.11B |
Operating Margin: | 0.14 | 0.15 | 0.20 |
Net Income: | 1.28B | 724.00M | 930.00M |
EPS: | 3.48 | 2.10 | 4.73 |
P/E: | 33.80 | 28.30 | 23.26 |
PEG (5 yr expected): | 1.30 | 1.94 | 1.95 |
P/S: | 3.16 | 2.85 | 2.60 |
Thermo Fisher has the highest P/S ratio among these three companies.
Here is a table of these competitors' insider-trading activities during the last 12 months.
Company | Insider buying / shares | Insider selling / shares |
A | 0 | 665,626 |
BDX | 0 | 142,842 |
Only Thermo Fisher has seen intensive insider selling during the last 30 days.
Conclusion
There have been four different insiders selling Thermo Fisher, and there have not been any insiders buying Thermo Fisher during the last 30 days. All four of these insiders decreased their holdings by more than 10%. Thermo Fisher has an insider ownership of 0.30%.
Before going short Thermo Fisher, I would like to get a bearish confirmation from the Point and Figure chart. The two main reasons for the proposed short entry are relatively high P/S ratio, and the intensive insider-selling activity.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)
This entry passed through the Full-Text RSS service — if this is your content and you're reading it on someone else's site, please read the FAQ at http://ift.tt/jcXqJW.
Aucun commentaire:
Enregistrer un commentaire